Trial Profile
A phase III, randomized, multi-center, double-blind, parallel-group, placebo-controlled safety and efficacy study of SPD503 [Intuniv; guanfacine] in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2021
Price :
$35
*
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 29 Jul 2018 Results of post hoc analysis of four studies (SPD503-301, SPD503-304, SPD503-312 and SPD503-316) published in the European Neuropsychopharmacology
- 07 May 2008 Results of a pooled analysis presented at APS 2008, according to a Shire media release.
- 30 Jan 2008 Results have been published (1101050)